IMR's Principal Activity is the design, manufacture and sell MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias.
Last (Price) | |
Change | 0.00 (0.00) |
Bid / Ask | - |
Volume | |
Volume (4w avg) | |
Turnover | |
Open | |
Day Range | - |
VWAP | |
Prev Close | |
Last Trade |
1 Week | |
1 Month | |
2022 YTD | |
1 Year | |
vs Sector (1yr) | -77.31% |
vs ASX 200 (1yr) | -84.46% |
Date | Heading | Pages | File Size | Time |
---|---|---|---|---|
Imricor Medical Systems Inc (IMR) is a US based medical device company that seeks to address the current issues with traditional x-ray-guided ablation procedures through the development of MRI-guided technology. The Company's primary product offering, the Vision-MR Ablation Catheter is specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters.
No incorporation details available.
Head Office | Burnsville Minnesot USA 55337 |
Website | www.imricor.com |
Registry | Computershare |
Auditor | Baker Tilly Virchow Krause, LLP |
Date Listed | 30 Aug 2019 |
Date | Event |
---|---|
25/08/2022 | Report (Interim) |
23/02/2023 | Report (Prelim) |
07/04/2023 | Report (Annual) |
DPS and Yield calculations use the Pay Date.
See Upcoming Dividends for all ASX companies.
IMR directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
The current holdings of IMR directors.
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
Name | Last Notice | Total Shares | Shares Held (%) |
---|---|---|---|
Warren G Herreid II and KAHR Foundation | 23/03/2022 | 10,771,092 | 7.52 |
BlackRock Group | 23/03/2022 | 17,529,317 | 12.23 |
Regal Funds Management Pty Limited | 23/03/2022 | 8,311,716 | 5.80 |
Siemens Medical Solutions USA Inc | 23/03/2022 | 8,384,150 | 5.85 |
Saville Capital | 23/03/2022 | 7,180,000 | 5.01 |
12 month transaction history compiled from ASX announcements.
Date | Name | Bought | Previous % | New % |
---|---|---|---|---|
07-01-22 | BlackRock Group | 1,740,473 | 11.02 | 12.23 |
22-10-21 | BlackRock Group | 15,788,844 | -- | 11.02 |
20-09-21 | BlackRock Investment Management Australia | 7,596,885 | 6.98 | 10.86 |
14-09-21 | Regal Funds Management Pty Limited | 8,311,716 | -- | 5.84 |
10-09-21 | One Funds Management Ltd | 7,180,000 | -- | 5.05 |
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
Date | Close | Change | %Chg | Open | High | Low | Volume | Turnover |
---|---|---|---|---|---|---|---|---|
Year | Closing Price | Last Trade |
---|---|---|
2021 | $1.95 | 30 June |
2020 | $1.49 | 30 June |
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.